Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
GoodRx Holdings ( (GDRX) ) has shared an announcement.
On June 3, 2025, GoodRx Holdings, Inc. conducted its Annual Meeting of Stockholders, where significant decisions were made regarding the company’s governance and financial oversight. Stockholders elected three Class II directors, ratified the appointment of PricewaterhouseCoopers LLP as the independent public accounting firm for 2025, and approved the executive compensation plan, reflecting strong shareholder support for the company’s leadership and strategic direction.
The most recent analyst rating on (GDRX) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on GoodRx Holdings stock, see the GDRX Stock Forecast page.
Spark’s Take on GDRX Stock
According to Spark, TipRanks’ AI Analyst, GDRX is a Neutral.
GoodRx Holdings demonstrates strong financial performance and a resilient financial structure, reflected in high profitability margins and effective cash generation. The recent earnings call indicates growth potential but highlights risks such as the Rite Aid bankruptcy and macroeconomic challenges. Technical indicators and valuation metrics suggest caution, as the stock trades below key moving averages and may be overvalued based on its P/E ratio.
To see Spark’s full report on GDRX stock, click here.
More about GoodRx Holdings
GoodRx Holdings, Inc. operates in the healthcare industry, primarily offering services that help consumers find affordable prescription medications. The company focuses on providing price transparency and discounts for prescription drugs to improve access to healthcare.
Average Trading Volume: 1,457,387
Technical Sentiment Signal: Sell
Current Market Cap: $1.36B
For an in-depth examination of GDRX stock, go to TipRanks’ Stock Analysis page.